ValiRx plc (LON:VAL) shares dropped 9.6% on Tuesday . The company traded as low as GBX 2.55 ($0.03) and last traded at GBX 2.60 ($0.04). Approximately 3,337,319 shares changed hands during mid-day trading, a decline of 13% from the average daily volume of 3,820,000 shares. The stock had previously closed at GBX 2.88 ($0.04).

ValiRx (LON:VAL) last issued its quarterly earnings data on Tuesday, April 10th. The company reported GBX (1.90) (($0.03)) earnings per share for the quarter, beating the Zacks’ consensus estimate of GBX (2.60) (($0.04)) by GBX 0.70 ($0.01).

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in developing technologies and products in oncology therapeutics and diagnostics in the United Kingdom and rest of Europe. The company operates in two segments, Drug Development and Sale of Self-Test Drug Kits. Its proprietary GeneICE technology enables selective silencing of genes by targeted histone deacetylation that leads to chromatin condensation.

Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with's FREE daily email newsletter.